More news: Research
Agency / Source: Trevigen, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Trevigen Announces HT PARP in Vivo Pharmacodynamic Assay II - Trevigen announces a validated assay, with higher sensitivity and pre-coated antibody plates to measure the effectiveness of PARP inhibitors in cell and tissue lysates for anticancer drug screening
Trevigen Announces HT PARP in Vivo Pharmacodynamic Assay II

 

PRZOOM - /newswire/ - Gaithersburg, MD, United States, 2010/01/31 - Trevigen announces a validated assay, with higher sensitivity and pre-coated antibody plates to measure the effectiveness of PARP inhibitors in cell and tissue lysates for anticancer drug screening.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Pharmacodynamic (PD) assays have recently been developed and employed early in the drug screening process to assess the ability of potential drug candidates to affect molecular targets. These assays have the advantages of performing molecular proof-of-concept investigations at an early stage such as phase 0 trials, and later can be used to stratify patients into treatment pools during any stage of clinical assessment.

In cancer drug development, a current molecular target of high interest is poly(ADP-ribose) polymerase (PARP), as it is intimately involved in DNA repair and the survival or death of cancer cells. Until now, measuring the effectiveness of PARP inhibitors in cell and tissue lysates has been difficult and time consuming due to a lack of refined immunological reagents in an optimized and quantitative assay. Traditional PARP assays require the transfection of damaged DNA into the cells of interest in order to measure endogenous PARP activity, an especially difficult step when assaying cells from tissues.

Trevigen addresses this problem with the release of the HT PARP in vivo Pharmacodynamic Assay II, which is a high throughput, Chemiluminescent, PAR ELISA assay kit that has been validated on human peripheral blood lymphocytes and also shown to work with normal and tumor tissue. This improved assay features:

• Pre-coated capture antibody plates.
• Broad linear dynamic range to 1,000 pg/ml.
• High signal to noise ratio.
• Detection sensitivity of 2 pg/ml of PAR.

The amount of PAR present correlates directly with the activity of the PARP enzyme in cell lysates. This assay is ideal for quantification of PAR in peripheral blood mononuclear cells, tissues and cultured cells.

Related Products from Trevigen (trevigen.com) include PARP and PARG assay and cellular differentiation kits, PARP enzymes and PARP antibodies. Visit the Trevigen website or contact us at 1-800-873-8443 for more information.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Trevigen, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


Trevigen Announces HT PARP in Vivo Pharmacodynamic Assay II

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Trevigen, Inc. |
Contact: Jennifer Garms - Trevigen.com 
301-216-2800 info[.]trevigen.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Trevigen, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Trevigen, Inc. / Company Profile


Read Research Most Recent Related Press Releases:

Avance Clinical Honored with Frost & Sullivan’s 2025 Global Customer Value Leadership Award for Transformative Biotech CRO Services
Safran, INSA Rouen Normandie, the University of Rouen Normandie and the CNRS Launch 'FLAMES', their Joint Research Laboratory
ENPC and VINCI Enter into A Strategic Partnership Around Environmental Transition and Digital Transformation
Reborna Biosciences, Inc. Enters into a Research and Licensing Agreement with Ono Pharmaceutical
Southern Star Research Applauded by Frost & Sullivan for Delivering Comprehensive Clinical Trial Solutions and its Competitive Strategies
GCCL Applauded by Frost & Sullivan for Ensuring Consistent, Reliable Clinical Trial Data in APAC
Medeze Group Awarded Frost & Sullivan’s 2024 Southeast Asia Company of the Year for Delivering Highly Innovative Stem Cell and Longevity Solutions
World Congress DSA 2025 - The Frontiers in Intelligent Data and Signal Analysis, Dresden Germany July
Motorola Solutions Announces New Global R&D Centre in Ireland
Naval Group Announces A New Collaboration Between Public and Private Research Studying the Electromagnetism of Ships

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  RightITnow, Inc.

Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2005-2026 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today